Clinical Trial Update: Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a combination of ibrutinib and ixazomib citrate in newly diagnosed, relapsed, or refractory Waldenström macroglobulinemia was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Ixazomib citrate (Ixazomib)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 2 | Status: TERMINATED | Results posted: 2025-09-18